Nuveen Asset Management, LLC Rain Therapeutics Inc. Transaction History

Nuveen Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.84 - $1.22 $14,054 - $20,411	16,731 New	16,731 $20,000
Q2 2022 Aug 15, 2022	SELL	$2.21 - $5.56 $71,685 - $180,349	-32,437 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$11.91 - $17.0 $148,577 - $212,075	12,475 Added 62.49%	32,437 $400,000
Q3 2021 Nov 12, 2021	BUY	$13.21 - $20.91 $110,237 - $174,493	8,345 Added 71.83%	19,962 $317,000
Q2 2021 Aug 16, 2021	BUY	$15.08 - $20.3 $175,184 - $235,825	11,617 New	11,617 $181,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.